Bio-Rad Laboratories, Inc.
BIO
$240.95
-$12.21-4.82%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.16B | -1.84B | -778.68M | -1.33B | -322.36M |
| Total Depreciation and Amortization | 152.60M | 151.60M | 149.60M | 148.00M | 147.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.16B | 2.77B | 1.45B | 2.16B | 860.04M |
| Change in Net Operating Assets | -631.20M | -620.80M | -413.00M | -636.20M | -338.50M |
| Cash from Operations | 515.31M | 455.21M | 412.01M | 346.16M | 346.58M |
| Capital Expenditure | -159.82M | -165.62M | -164.98M | -168.82M | -161.18M |
| Sale of Property, Plant, and Equipment | 74.00K | 74.00K | 219.00K | 227.00K | 200.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 2.50M | 2.50M | 2.50M |
| Other Investing Activities | 45.54M | 5.34M | 104.78M | 154.75M | 206.05M |
| Cash from Investing | -114.21M | -160.21M | -57.47M | -11.34M | 47.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -382.00K | -482.00K | -592.00K | -587.00K | -585.00K |
| Issuance of Common Stock | 18.00M | 19.20M | 19.62M | 19.16M | 19.58M |
| Repurchase of Common Stock | -304.15M | -206.95M | -411.57M | -341.73M | -448.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.98M | -30.58M | -600.00K | -600.00K | -600.00K |
| Cash from Financing | -316.52M | -218.82M | -393.15M | -323.76M | -429.91M |
| Foreign Exchange rate Adjustments | 4.74M | 9.24M | -7.48M | 6.26M | 5.10M |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 52.00K | 0.00 | 0.00 |
| Net Change in Cash | 89.32M | 85.42M | -46.04M | 17.33M | -30.66M |